CureVac NV Cash Flow Conversion Efficiency
CureVac NV cash flow conversion efficiency. Based on the latest financial reports, CureVac NV (5CV) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€29.86 Million ≈ $34.91 Million USD) by net assets (€871.23 Million ≈ $1.02 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CureVac NV (2018–2024)
Cash flow conversion efficiency of CureVac NV from 2018 to 2024. This chart illustrates how CureVac NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 5CV live share price for real-time trading data and today's change.
CureVac NV Cash Flow Conversion Ratio Explained
CureVac NV cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CureVac NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CureVac NV ranked by their cash flow conversion efficiency. Also see 5CV company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Generation Development Group Ltd
AU:GDG
|
0.037x |
|
Jade Biosciences, Inc.
NASDAQ:JBIO
|
-0.099x |
|
Neurones
PA:NRO
|
0.144x |
|
Japfa Comfeed Indonesia Tbk
JK:JPFA
|
-0.208x |
|
Suzhou Huaya Intelligence Technology Co Ltd
SHE:003043
|
0.014x |
|
CH. Karnchang PCL
BK:CK
|
0.046x |
|
Shanghai Prisemi Electronics Co Ltd
SHG:688230
|
0.012x |
|
BlackRock Credit Allocation Income Trust
NYSE:BTZ
|
0.029x |
Annual Cash Flow Conversion Efficiency for CureVac NV (2018–2024)
The table below shows the annual cash flow conversion efficiency of CureVac NV from 2018 to 2024. Review CureVac NV free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €696.61 Million ≈ $814.41 Million |
€101.85 Million ≈ $119.07 Million |
0.146x | +128.21% |
| 2023-12-31 | €516.94 Million ≈ $604.36 Million |
€-267.89 Million ≈ $-313.19 Million |
-0.518x | +3.44% |
| 2022-12-31 | €533.25 Million ≈ $623.43 Million |
€-286.18 Million ≈ $-334.57 Million |
-0.537x | +49.60% |
| 2021-12-31 | €688.48 Million ≈ $804.90 Million |
€-733.13 Million ≈ $-857.10 Million |
-1.065x | -245.00% |
| 2020-12-31 | €711.35 Million ≈ $831.64 Million |
€522.40 Million ≈ $610.74 Million |
0.734x | -63.85% |
| 2019-12-31 | €-42.80 Million ≈ $-50.04 Million |
€-86.96 Million ≈ $-101.67 Million |
2.032x | +187.96% |
| 2018-12-31 | €32.08 Million ≈ $37.51 Million |
€-74.11 Million ≈ $-86.64 Million |
-2.310x | -- |
About CureVac NV
As of December 18, 2025, CureVac N.V. was acquired by BioNTech SE. CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company's portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRN… Read more